Scancell Holdings Plc Appoints Heads of Research and Manufacturing
21 January 2019 - 6:00PM
RNS Non-Regulatory
TIDMSCLP
Scancell Holdings Plc
21 January 2019
21 January 2019
Scancell Holdings Plc
("Scancell" or the "Company")
Scancell appoints Head of Research and Head of Manufacturing
Samantha Paston, PhD appointed Head of Research; Adrian Parry,
PhD appointed Head of Manufacturing
Appointments add significant expertise to further advance
Scancell's pipeline of cancer immunotherapies
Scancell Holdings plc, the developer of novel immunotherapies
for the treatment of cancer, today announces the appointment of Dr
Samantha Paston as Head of Research and Dr Adrian Parry as Head of
Manufacturing. Dr Paston started in her role in mid-January and Dr
Parry will start in his role on 01 February 2019.
Dr Samantha Paston joins Scancell from Immunocore where she has
held several positions since June 2008 including Head of T Cell
Cloning and Group Leader. While at Immunocore Samantha was
responsible for the generation of the in house T cell cloning
method and biological molecule discovery which made significant
contributions to the current Immunocore oncology pipeline. Prior to
this, Samantha held a number of positions at Medigene, Avidex,
NIBSC and GSK. Samantha holds a PhD from University College London
in Immunology/Haematology, following an BSc Honours Degree in
Microbiology from the University of Sheffield. Based at the
Company's corporate offices in Oxford, Samantha will report
directly to Scancell's founder and Chief Scientific Officer,
Professor Lindy Durrant who commented: "Samantha will be invaluable
in immunological design of the upcoming trials and spearheading the
new TCR therapeutics and I am very excited to add such an
experienced scientist to the team."
Dr Adrian Parry joins Scancell from Mereo BioPharma where he was
Head of Small Molecule CMC (Chemistry, Manufacturing and Controls),
managing outsourced GMP manufacturing activities to support their
clinical trials. Prior to this, Adrian was New Product Development
Director at Juniper Pharmaceuticals where he managed and
coordinated preclinical and CMC development activities. Adrian has
previously held further CMC positions at Circassia, Shire
Pharmaceuticals, Prosidion, Evotec and OSI Pharmaceuticals,
totalling 20 years of development expertise including the delivery
of multiple, complex GMP drug products with associated regulatory
submissions in Europe and the US. Adrian holds a PhD in Physical
Organic/Analytical Chemistry from The Open University, following a
MSc in Advanced Analytical Chemistry from the University of
Bristol. Adrian will also be based in the Oxford offices and will
report to Dr Sally Adams, Scancell's Development Director.
Cliff Holloway, CEO of Scancell, commented:
"We are delighted to welcome both Samantha and Adrian to
Scancell. Samantha's experience in T cell cloning and working with
biological molecules, from drug discovery through to early
development, will be invaluable as we continue to progress our
pipeline of cancer immunotherapies. Likewise, Adrian's 20 years of
CMC and GMP development expertise will be key for our manufacturing
capabilities moving forward.
These two appointments are significant for Scancell as we expand
our R&D and manufacturing capabilities in order to further
advance our ImmunoBody(R) and Moditope(R) pipeline products through
clinical development."
For Further Information:
Scancell Holdings Plc
Dr John Chiplin, Chairman +44 (0) 20 3727 1000
Dr Cliff Holloway, CEO
Panmure Gordon (UK) Limited
(Nominated Adviser and Corporate
broker)
Freddy Crossley/Emma Earl +44 (0) 20 7886 2500
FTI Consulting
Simon Conway/Natalie Garland-Collins +44 (0) 20 3727 1000
About Scancell
Scancell is developing novel immunotherapies for the treatment
of cancer based on its ImmunoBody(R) and Moditope(R) technology
platforms.
ImmunoBody(R) vaccines target dendritic cells and stimulate both
parts of the cellular immune system. They can be used as
monotherapy or in combination with checkpoint inhibitors. This
platform has the potential to enhance tumour destruction, prevent
disease recurrence and extend survival.
-- SCIB1, the lead programme, is being developed for the
treatment of melanoma. A phase 1/2 clinical trial has so far
successfully demonstrated survival data of more than five
years.
-- SCIB2 is being developed for the treatment of non-small cell
lung cancer and other solid tumours. Scancell has entered into a
clinical development partnership with Cancer Research UK for
SCIB2.
Moditope(R) represents a completely new class of potent and
selective immunotherapy agents. It stimulates the production of
killer CD4+ T cells which overcome the immune suppression induced
by tumours. allowing activated T cells to seek out and kill tumour
cells that would otherwise be hidden from the immune system.
Moditope(R) alone, or in combination with other agents, has the
potential to treat a wide variety of cancers.
-- Modi-1 is being developed for the treatment of triple
negative breast cancer, ovarian cancer and sarcomas.
For further details, please see our website:
www.scancell.co.uk
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRADMGMMKRZGLZM
(END) Dow Jones Newswires
January 21, 2019 02:00 ET (07:00 GMT)
Scancell (LSE:SCLP)
Historical Stock Chart
From Apr 2024 to May 2024
Scancell (LSE:SCLP)
Historical Stock Chart
From May 2023 to May 2024